XML 21 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
Consolidated Statements of Operations - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Revenues $ 8,300,439 $ 5,866,963 $ 15,789,918 $ 9,039,242
Cost of revenues 7,051,546 5,798,796 13,279,802 9,167,408
Research and development 4,027,965 7,600,744 9,904,143 14,404,376
Impairment of intangible assets 0 9,400,000 0 9,400,000
Selling, general, and administrative 4,705,879 8,736,373 11,164,210 19,824,272
Total operating costs and expenses 15,785,390 31,535,913 34,348,155 52,796,056
Operating loss (7,484,951) (25,668,950) (18,558,237) (43,756,814)
Other income (expense):        
Other income (expense), net 6,860 5,354,845 12,545 4,808,818
Interest expense (359,725) (547,275) (1,286,542) (1,098,239)
Nonoperating Income (Expense), Total (352,865) 4,807,570 (1,273,997) 3,710,579
Loss before provision for income taxes and noncontrolling interests (7,837,816) (20,861,380) (19,832,234) (40,046,235)
Provision (benefit) for income taxes 46,954 (3,703,363) 100,332 (3,656,730)
Net loss (7,884,770) (17,158,017) (19,932,566) (36,389,505)
Less - loss attributable to noncontrolling interests (50,054) (31,757) (116,933) (76,349)
Net loss attributable to Caladrius Biosciences, Inc. common stockholders $ (7,834,716) $ (17,126,260) $ (19,815,633) $ (36,313,156)
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders $ (1.33) $ (3.84) $ (3.39) $ (8.83)
Weighted average common shares outstanding 5,907,013 4,457,480 5,839,963 4,110,413
Available for sale securities - net unrealized (loss) gain $ 0 $ 1,866 $ (486) $ 537
Total other comprehensive loss 0 1,866 (486) 537
Comprehensive loss (7,884,770) (17,156,151) (19,933,052) (36,388,968)
Comprehensive loss attributable to noncontrolling interests (50,054) (31,757) (116,933) (76,349)
Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders $ (7,834,716) $ (17,124,394) $ (19,816,119) $ (36,312,619)